Edition:
United States

SciClone Pharmaceuticals Inc (SCLN.OQ)

SCLN.OQ on NASDAQ Stock Exchange Global Select Market

11.10USD
4:00pm EDT
Change (% chg)

$0.05 (+0.45%)
Prev Close
$11.05
Open
$11.00
Day's High
$11.10
Day's Low
$11.00
Volume
55,137
Avg. Vol
104,132
52-wk High
$11.40
52-wk Low
$8.60

SCLN.OQ

Chart for SCLN.OQ

About

SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World,... (more)

Overall

Beta: 1.73
Market Cap(Mil.): $576.72
Shares Outstanding(Mil.): 52.19
Dividend: --
Yield (%): --

Financials

  SCLN.OQ Industry Sector
P/E (TTM): 12.85 31.59 32.70
EPS (TTM): 0.86 -- --
ROI: 19.55 15.32 14.88
ROE: 19.56 16.34 16.12

BRIEF-SciClone announces end of go-shop period with no parties designated as excluded parties

* Sciclone announces end of go-shop period with no parties designated as excluded parties

Aug 10 2017

BRIEF-SciClone Q2 non-GAAP earnings per share $0.30

* SciClone Pharmaceuticals Inc - ‍in light of pending merger, company will not be updating its guidance for fiscal 2017​

Aug 09 2017

BRIEF-Man Group plc reports 5.48 pct stake in Sciclone Pharmaceuticals Inc as of July 18 - SEC FILING

* Man Group plc reports 5.48 percent stake in Sciclone Pharmaceuticals Inc as of july 18 - SEC FILING

Jul 27 2017

BRIEF-Sciclone Pharmaceuticals - Sciclone Pharmaceuticals merger deal with consortium led by Gl Capital's termination fee set at $15.8 mln ‍​

* Sciclone Pharmaceuticals - sciclone pharmaceuticals merger deal with consortium led by gl capital's termination fee set at $15.8 million - sec filing‍​ ‍​

Jun 08 2017

BRIEF-SciClone to be acquired by consortium led by GL Capital

* SciClone enters into definitive merger agreement to be acquired by consortium led by GL Capital

Jun 08 2017

BRIEF-SciClone Pharmaceuticals to be acquired by Consortium Led by GL Capital

* Sciclone Pharmaceuticals Inc says deal for $11.18 per share Sciclone enters into definitive merger agreement to be acquired by consortium led by GL capital

Jun 08 2017

BRIEF-Sciclone reports Q1 revenue $42.9 million

* Q1 GAAP earnings per share $0.28 Source text for Eikon: Further company coverage:

May 10 2017

BRIEF-Sciclone Pharma files for mixed shelf of upto $100 mln

* Sciclone Pharmaceuticals Inc - files for mixed shelf of upto $100 million - SEC filing Source text: (http://bit.ly/2m7KZfv) Further company coverage:

Mar 09 2017

BRIEF-SciClone reports Q4 revenue of $44.1 million

* SciClone Pharmaceuticals Inc- SciClone projects its 2017 revenue to be in range between $170 and $175 million

Mar 06 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $132.63 -0.41
Novartis AG (NOVN.S) CHF79.80 -0.85
Pfizer Inc. (PFE.N) $32.67 -0.28
Merck & Co., Inc. (MRK.N) $61.49 -0.32
Amgen, Inc. (AMGN.OQ) $167.29 -0.52
Gilead Sciences, Inc. (GILD.OQ) $72.11 -0.23

Earnings vs. Estimates